Posted by Michael Wonder on 13 Mar 2019
Foquest receives approval for expanded indication for children and adolescents with ADHD
12 March 2019 - First and only methylphenidate product approved in Canada that provides control of ADHD symptoms throughout the day.
Purdue Pharma announced today that Health Canada has issued a Notice of Compliance for an expanded indication for Foquest (methylphenidate hydrochloride controlled-release capsules), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents six years of age and older. This announcement follows the 6 December 2017 Notice of Compliance for Foquest for the treatment of ADHD in adults 18 years of age and older.
Foquest is the first methylphenidate product approved in Canada that provides ADHD patients with symptom control throughout the day, and an onset of action within one hour.
